Literature DB >> 8068412

Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine.

R C Desrosiers.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8068412     DOI: 10.1089/aid.1994.10.331

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  11 in total

1.  Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

Authors:  L D Giavedoni; T Yilma
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 2.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques.

Authors:  Géraldine Arrode-Brusés; Ramakrishna Hegde; Yuhuai Jin; Zhengian Liu; Opendra Narayan; Yahia Chebloune
Journal:  Vaccine       Date:  2012-03-02       Impact factor: 3.641

4.  A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus.

Authors:  R C Desrosiers; V G Sasseville; S C Czajak; X Zhang; K G Mansfield; A Kaur; R P Johnson; A A Lackner; J U Jung
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

Review 5.  Vaccines for control of AIDS--an update.

Authors:  K B Sharma
Journal:  Indian J Pediatr       Date:  1994 Sep-Oct       Impact factor: 1.967

6.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.

Authors:  J P McGettigan; H D Foley; I M Belyakov; J A Berzofsky; R J Pomerantz; M J Schnell
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.

Authors:  Helen Horton; Thorsten U Vogel; Donald K Carter; Kathy Vielhuber; Deborah H Fuller; Tim Shipley; James T Fuller; Kevin J Kunstman; Gerd Sutter; David C Montefiori; Volker Erfle; Ronald C Desrosiers; Nancy Wilson; Louis J Picker; Steven M Wolinsky; Chenxi Wang; David B Allison; David I Watkins
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  A candidate live inactivatable attenuated vaccine for AIDS.

Authors:  B K Chakrabarti; R K Maitra; X Z Ma; H W Kestler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus.

Authors:  Tomek Swigut; Louis Alexander; Jennifer Morgan; Jeff Lifson; Keith G Mansfield; Sabine Lang; R Paul Johnson; Jacek Skowronski; Ronald Desrosiers
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.